Loading
A phase 3 trial testing XZP-3287 in HR-positive / HER2-negative breast cancer, active and no longer recruiting.
A Study of XZP-3287 in Combination With Fulvestrant in Patients With Advanced Breast Cancer is a phase 3 interventional study registered as NCT05077449, led by Xuanzhu Biopharmaceutical, and active but no longer recruiting on the registry. Official title: A Phase III Study to Evaluate the Efficacy and Safety of XZP-3287 in Combination With Fulvestrant Versus Placebo Combined With Fulvestrant in Patients With HR Positive and HER2 Negative Recurrent/Metastatic Breast Cancer. Planned enrolment is 300 participants (estimated). The study started in 2021-11-16 and primary completion is expected in 2024-02-22. No results have been posted on ClinicalTrials.gov.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/